Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testing

Join Mayo Clinic Laboratories and C2N Diagnostics for our webinar exploring how the evolution of blood biomarker testing for Alzheimer's disease has expanded access to earlier, less-invasive diagnosis. Focusing on the newly FDA-cleared PrecivityAD2 blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how results from blood biomarker testing can support timely diagnosis, informed clinical decision-making, and improved patient care.

On Thursday, Oct. 29, from 11 a.m. to noon CT, learn more about the evolving diagnostic landscape of Alzheimer’s disease and why PrecivityAD2 testing is at the leading edge of early detection of amyloid pathology and Alzheimer’s disease diagnosis. This webinar is presented by Matthew Binnicker, Ph.D., chief scientific officer for Mayo Clinic Laboratories; Ronald Petersen, M.D., Ph.D., professor of neurology at Mayo Clinic; and Joel Braunstein, M.D., MBA, co-founder and CEO of C2N Diagnostics.

Don't miss this opportunity to learn how the latest clinical insights on Alzheimer’s disease diagnosis along with the noninvasive, PrecivityAD2 blood test can improve early detection for Alzheimer’s disease.

For questions, contact us at mcleducation@mayo.edu.

Register now

Robin Huiras

Robin Huiras is a senior marketing specialist at Mayo Clinic Laboratories and a Mayo Clinic employee since 2015. Her writing focuses on specialty testing, innovation, and patient-focused initiatives.

Related Posts

Ace Your Interview: Strategies for Success featured image
Ace Your Interview: Strategies for Success
September 14, 2026

Review how to communicate your strengths, share meaningful examples, and ask thoughtful questions that may reveal team culture and expectations.
Metagenomic sequencing: A revolutionary approach to aid in the diagnosis of serious and complex infections featured image
Metagenomic sequencing: A revolutionary approach to aid in the diagnosis of serious and complex infections
August 28, 2026

Join Mayo Clinic Laboratories for our webinar exploring the expanding role of precision diagnostics in the evaluation of serious and potentially life-threatening infections. Focusing on metagenomic sequencing available from Mayo Clinic Laboratories, including the Karius Spectrum plasma test, which is offered by Mayo Clinic Laboratories in collaboration with Karius, participants will gain an overview of microbial cell-free DNA (mcfDNA) metagenomic sequencing, including clinical decision-making around test ordering, appropriate clinical indications, and how to interpret and apply results to support timely diagnosis and patient management.
Using AI and Digital Slide Scanning To Detect Intestinal Protozoa featured image
Using AI and Digital Slide Scanning To Detect Intestinal Protozoa
August 24, 2026

Explore why traditional microscopy is challenging, how AI-assisted review works, what workflow changes are required, and how validation data can support implementation decisions.